Enhancing autophagy or increasing longevity by administration of urolithins

Patent metadata

Field	Value
Publication number	US-12544358-B2
Application number	US-202318130246-A
Country	US
Kind code	B2
Filing date	Apr 3, 2023
Priority date	Jun 27, 2012
Publication date	Feb 10, 2026
Grant date	Feb 10, 2026

Abstract

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

First claim

We claim:

1 . A composition, comprising urolithin A or a pharmaceutically acceptable salt thereof; and a second ingredient selected from the group consisting of resveratrol and coenzyme Q10; wherein the coenzyme Q10 is ubiquinol or ubiquinone.

2 . The composition of claim 1 , wherein the second ingredient is resveratrol.

3 . The composition of claim 1 , wherein the second ingredient is coenzyme Q10; and the coenzyme Q10 is ubiquinol.

4 . The composition of claim 1 , wherein the second ingredient is coenzyme Q10; and the coenzyme Q10 is ubiquinone.

5 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

6 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 1 .

7 . The method of claim 6 , wherein the mitochondrial function is mitophagy.

8 . The composition of claim 2 , further comprising a pharmaceutically acceptable carrier.

9 . The composition of claim 3 , further comprising a pharmaceutically acceptable carrier.

10 . The composition of claim 4 , further comprising a pharmaceutically acceptable carrier.

11 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 2 .

12 . The method of claim 11 , wherein the mitochondrial function is mitophagy.

13 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 3 .

14 . The method of claim 13 , wherein the mitochondrial function is mitophagy.

15 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 4 .

16 . The method of claim 15 , wherein the mitochondrial function is mitophagy.

17 . The composition of claim 2 , wherein the composition is in the form of a dietary supplement or a nutraceutical.

18 . The composition of claim 3 , wherein the composition is in the form of a dietary supplement or a nutraceutical.

19 . The composition of claim 4 , wherein the composition is in the form of a dietary supplement or a nutraceutical.

Assignees

• Amazentis Sa

Inventors

• Rinsch Christopher L
• Blanco-Bose William
• Schneider Bernard
• Mouchiroud Laurent
• Ryu Dongryeol
• Andreux Penelope
• Auwerx Johan

Classifications

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/366 Primary

  having six-membered rings, e.g. delta-lactones · CPC title

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07D311/80

  Dibenzopyrans; Hydrogenated dibenzopyrans · CPC title